Table 1.
Associations between RXRG expression and clinicopathological features in the whole series, ER-positive and ER-Negative breast cancer series
| Parameters | RXRG expression whole cohort | RXRG expression ER-positive cohort | RXRG expression ER-negative cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Negative/ low expression N (%) | High expression N (%) | p-value (χ2) | Negative/ low expression N (%) | High expression N (%) | p-value (χ2) | Negative/ low expression N (%) | High expression N (%) | p-value (χ2) | |
| Age at diagnosis (years) | |||||||||
| <50 | 167 (51.2) | 159 (48.8) | 1.473 (0.520) | 94 (43.3) | 123 (56.7) | 1.239 (0.682) | 72 (68.6) | 33 (31.4) | 0.123 (2.673) |
| ≥50 | 291 (48.7) | 306 (51.3) | 225 (46.7) | 257 (53.3) | 66 (57.9) | 48 (42.1) | |||
| Histological grade | |||||||||
| 1 | 52 (35.6) | 94 (64.4) | <0.00001 (44.423) | 49 (35.8) | 88 (64.2) | <0.00001 (25.929) | 2 (40.0) | 3 (60.0) | 0.530 (1.271) |
| 2 | 130 (40.8) | 189 (59.2) | 122 (39.9) | 184 (60.1) | 8 (61.5) | 5 (38.5) | |||
| 3 | 273 (60.9) | 175 (39.1) | 145 (58.5) | 103 (41.5) | 128 (63.6) | 71 (35.7) | |||
| Tubules | |||||||||
| 1 | 11 (26.2) | 31 (73.8) | 0.004 (13.895) | 11(27.5) | 29 (72.5) | 0.172 (6.284) | 0 (0.0) | 1 (100.0) | 0.376 (1.959) |
| 2 | 140 (46.1) | 164 (53.9) | 123 (44.2) | 155 (55.8) | 17 (68.0) | 8 (32.0) | |||
| 3 | 289 (53.4) | 252 (46.6) | 169 (48.0) | 183 (52.0) | 120 (63.5) | 69 (36.5) | |||
| Pleomorphism | |||||||||
| 1 | 5 (23.8) | 16 (76.2) | <0.00001 (23.960) | 5 (26.3) | 14 (73.7) | 0.042 (10.294) | 0 (0.0) | 1 (100.0) | 0.406 (1.803) |
| 2 | 144 (41.4) | 204 (58.6) | 136 (40.6) | 199 (59.4) | 8 (66.7) | 4 (33.3) | |||
| 3 | 291 (56.2) | 227 (43.8) | 162 (51.3) | 154 (48.7) | 129 (63.9) | 73 (36.1) | |||
| Mitosis | |||||||||
| 1 | 111 (36.0) | 197 (64.0) | <0.00001 (53.653) | 107 (36.0) | 190 (64.0) | <0.00001 (22.597) | 4 (44.4) | 5 (55.6) | 0.170 (3.452) |
| 2 | 77 (43.3) | 101 (56.7) | 67 (42.4) | 91 (57.6) | 10 (50.0) | 10 (50.0) | |||
| 3 | 252 (62.8) | 149 (37.2) | 129 (60.0) | 86 (40.0) | 123 (66.1) | 63 (33.9) | |||
| Stage | |||||||||
| I | 280 (50.5) | 275 (49.5) | 1.69 (0.337) | 203 (47.6) | 221 (52.4) | 1.064 (2.200) | 80 (60.6) | 52 (39.4) | 0.522 (1.300) |
| II | 141 (49.1) | 146 (50.9) | 97 (43.7) | 125 (56.3) | 43 (68.3) | 20 (31.7) | |||
| III | 34 (47.2) | 38 (52.8) | 19 (38.0) | 31 (62.0) | 15 (68.2) | 7 (31.8) | |||
| Tumour size | |||||||||
| <2.0 cm | 182 (42.8) | 243 (57.2) | 0.0005 (15.355) | 143 (40.6) | 209 (59.4) | 0.036 (7.550) | 38 (54.3) | 32 (45.7) | 0.071 (3.609) |
| ≥2.0 cm | 274 (55.8) | 217 (44.2) | 174 (51.0) | 167 (49.0) | 100 (67.6) | 48 (32.4) | |||
| Histological type | |||||||||
| Ductal | 403 (53.3) | 353 (46.7) | 0.0001 (29.455) | 277 (49.5) | 283 (50.5) | 0.016 (19.281) | 125 (64.8) | 68 (35.2) | 0.071 (10.161) |
| Lobular | 32 (32.3) | 67 (67.7) | 32 (33.0) | 65 (67.0) | 0 (0.00) | 2 (100.0) | |||
| Medullary-like | 12 (57.1) | 9 (42.9) | 1 (50.0) | 1 (50.0) | 11 (57.9) | 8 (42.1) | |||
| Special typea | 8 (22.2) | 28 (77.8) | 6 (18.8) | 26 (81.3) | 2 (100.0) | 0 (0.0) | |||
| IHC subtypes | |||||||||
| ER+/HER2– low proliferation | 78 (36.4) | 136 (63.6) | <0.00001 (37.474) | 78 (36.4) | 136 (63.6) | 0.009 (14.564) | 0.103 (2.849) | ||
| ER+/HER2 – high proliferation | 147 (50.3) | 145 (49.7) | 147 (50.3) | 145 (49.7) | |||||
| Triple negative | 102 (68.0) | 48 (32.0) | 102 (68.0) | 48 (32.0) | |||||
| HER2 + | 71 (57.3) | 53 (42.7) | 31 (55.4) | 25 (44.6) | |||||
| Nottingham Prognostic Index | |||||||||
| GPG | 105 (39.2) | 163 (60.8) | 0.0004 (19.294) | 101 (39.8) | 153 (60.2) | 0.040 (6.538) | 3 (30.0) | 7 (70.0) | 0.051 (5.943) |
| MPG | 260 (52.5) | 235 (47.5) | 165 (48.1) | 178 (51.9) | 95 (62.9) | 56 (37.1) | |||
| PPG | 91 (59.5) | 62 (40.5) | 51 (45.7) | 45 (46.9) | 40 (70.2) | 17 (29.8) | |||
Significant p-values are highlighted in bold;
GPG good prognostic group, MPG moderate prognostic group, PPG poor prognostic group
aSpecial types of excellent prognosis (invasive tubular, invasive cribriform, invasive mucinous, invasive papillary carcinoma)